Basaran, G. Et Al. 2020. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15 .

Basaran, G., Demirci, U., Yildiz, F., Cicin, I., Aktas, B. Y., Ozturk, B., ... Goksu, S. S.(2020). Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.

Basaran, Gul Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020

Basaran, Gul Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020

Basaran, G. Et Al. (2020) . "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.

@article{article, author={Gul Basaran Et Al. }, title={Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2020}